Trial Profile
A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms JeRiCHO
- 28 Nov 2022 Final Results published in the European Journal of Haematology
- 19 Jul 2019 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 19 Jul 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.